Selective (cardioselective) β1 adrenergic receptor blocker, with rapid onset, short duration of action, and no obvious intrinsic sympathomimetic activity or membrane stabilizing effect at therapeutic doses. The elimination half-life after intravenous injection is about 9 minutes. It mainly inhibits β1 adrenergic receptors located in the myocardium, and in large doses also has a blocking effect on β2 adrenergic receptors in tracheal and vascular smooth muscle.

It has an antitussive effect on mice with ammonia-induced cough, can increase the secretion of phenol red in the mouse trachea, and has a relaxant effect on isolated tracheal smooth muscle; it has the effect of promoting humoral immunity and cellular immunity in mice with tracheitis models, and has certain anti-inflammatory and anti-stress effects.

It has an antitussive effect on mice with ammonia-induced cough, can increase the secretion of phenol red in the mouse trachea, and has a relaxant effect on isolated tracheal smooth muscle; it has the effect of promoting humoral immunity and cellular immunity in mice with tracheitis models, and has certain anti-inflammatory and anti-stress effects.

Immunomodulatory drugs have the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

Pharmacodynamics: This product is an immunomodulatory drug. It has the function of regulating and enhancing the cellular immune function of the human body and can promote the maturation of T-lymphocytes.

Pentoxifylline and its metabolites can reduce blood viscosity and improve blood rheology. The exact mechanism of action has not yet been determined. Pentoxifylline has the effect of reducing blood viscosity, increasing red blood cell deformability, improving the blood rheology of white blood cells in a dose-dependent manner, and can inhibit the adhesion and activation of neutrophils. For patients with chronic peripheral arterial vascular disease, this product can increase blood flow, improve microcirculation and increase oxygen supply to tissues.

Pentoxifylline and its metabolites can reduce blood viscosity and improve blood rheology. The exact mechanism of action has not yet been determined. Pentoxifylline has the effect of reducing blood viscosity, increasing red blood cell deformability, improving the blood rheology of white blood cells in a dose-dependent manner, and can inhibit the adhesion and activation of neutrophils. For patients with chronic peripheral arterial vascular disease, this product can increase blood flow, improve microcirculation and increase oxygen supply to tissues.